Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 27 of 95, showing 5 Applications out of 474 total, starting on record 131, ending on 135

# Protocol No Study Title Investigator(s) & Site(s)

131.

ECCT/22/03/08   CVIA 092
    “ A Phase 3 Multicenter, Observer Blind, Randomized, Controlled Study to Evaluate Safety (Ages 6 Months to 45 Years) and Non-inferiority (Ages 9-12 Months) of Multi-dose and Single-dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) against Typbar TCV® and Lot-to-Lot Consistency of the Immune Response (Ages 9-12 Months) to Multi-dose Vial Formulation EuTCV in Healthy African Participants”.    
Principal Investigator(s)
1. Dr Lucy Koech Chepkurui Koech
Site(s) in Kenya
KEMRI/ KERICHO CRC
 
View

132.

ECCT/22/03/07   ELEVATUM
    A PHASE IIIB/IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE FARICIMAB (RO6867461) TREATMENT RESPONSE IN TREATMENT-NAÏVE, UNDERREPRESENTED PATIENTS WITH DIABETIC MACULAR EDEMA   
Principal Investigator(s)
1. Dr. Oscar Muwale Onyango
2. Dr. Muchai Gachago
Site(s) in Kenya
1. The Nairobi Hospital (Nairobi City county)
2. City Eye Hospital (Nairobi City county)
 
View

133.

ECCT/22/03/06   Sickle Cell Disease
    A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Janet Oyieko
2. Fredrick Chite Asirwa
3. Bernhards Ogutu
Site(s) in Kenya
1. Kombewa Clinical Research Centre (Kisumu county)
2. Victoria Biomedical Research institute (Kisumu county)
3. International Cancer Centre (Uasin Gishu county)
4. CREATES - Strathmore University Medical Centre (Nairobi City county)
 
View

134.

ECCT/22/03/05   CHAPATI
    CHildren treated with vincristine: A trial regarding Pharmacokinetics, DNA And Toxicity of targeted therapy In pediatric oncology patients.   
Principal Investigator(s)
1. FESTUS MUIGAI NJUGUNA
Site(s) in Kenya
Moi Teaching and Referral Hospital
 
View

135.

ECCT/22/03/04   VIBRI COVID-19-001/2021
    A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda).   
Principal Investigator(s)
1. Dr. Lucas Otieno Tina
Site(s) in Kenya
Victoria Biomedical Research Institute,
 
View